Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Clarinex Approval Comes In Time For Big Spring Push

Executive Summary

Schering-Plough has received approval for the Claritin successor Clarinex in time to permit a big market build-up for the spring allergy season

You may also be interested in...



Fair Remedy Or Illegal Penalty? FDA Disgorgement Authority Questioned

Congress should examine whether FDA has the authority to seek disgorgement of profits and restitution in enforcement actions, Hyman, Phelps & McNamara principal John Fleder said Sept. 22

Fair Remedy Or Illegal Penalty? FDA Disgorgement Authority Questioned

Congress should examine whether FDA has the authority to seek disgorgement of profits and restitution in enforcement actions, Hyman, Phelps & McNamara principal John Fleder said Sept. 22

Schering Clarinex Reditabs approved

Schering-Plough's Clarinex Reditabs 5 mg clears FDA June 26 for treatment of allergy symptoms and chronic idiopathic urticaria. Product launch is "pending FDA approval of a quality control test revision, the supplement for which has already been submitted, and the build-up of sufficient inventories," the company said. Reditabs have been "approvable" since December (1"The Pink Sheet" Dec. 24, 2001, p. 34)...

Related Content

UsernamePublicRestriction

Register

PS039065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel